Clinical Trials on Type I Hypersensitivity

Total 65035 results

Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Grass MATA MPL

Type I Hypersensitivity

United States, Canada, United Kingdom, Austria
Allergy Therapeutics

Completed

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

Type I Hypersensitivity

United States
Allergy Therapeutics

Completed

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

Type I Hypersensitivity

United States
Allergy Therapeutics

Completed

Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen

Type I Hypersensitivity

Germany
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Ragweed MATA MPL

Type I Hypersensitivity

Canada, United States
Allergy Therapeutics

Completed

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

Type I Hypersensitivity

United States
Allergy Therapeutics

Withdrawn

Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

United States
Allergy Therapeutics

Completed

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis

Type I Hypersensitivity

Canada
Allergy Therapeutics

Terminated

Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis

Type I Hypersensitivity

Canada
Creative Testing Solutions

Completed

Evaluation of InnoLIA HTLV I/II Score

Human T-Lymphotrophic Virus Type I and/or Type II

United States
HAE Global Registry Foundation

Recruiting

Global Registry to Gather Data on Natural History of Patients With Hereditary Angioedema Type I and II (HGR)

Hereditary Angioedema Type I and II

Italy
KalVista Pharmaceuticals, Ltd.

Completed

A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

Hereditary Angioedema

United States, Austria, Czechia, Germany, Hungary, Italy, Netherlands, North Macedonia, Poland, United Kingdom
Prothya Biosolutions

Completed

Kinetics, Efficacy and Safety of C1-Esteraseremmer-N

Hereditary Angioedema Type I | Angioneurotic Edema

Netherlands
CENTOGENE GmbH Rostock

Completed

Biomarker for Hereditary AngioEdema Disease (BioHAE)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | C1 Esterase Inhibitor Deficiency | HAE | Angio Edema | C4 Deficiency | Hereditary Angioedema Type III

Turkey, Armenia, Georgia, India, Peru, Poland, Romania
Pharvaris Netherlands B.V.

Completed

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-1)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

Bulgaria, United States, Spain, Israel, Germany, Canada, Czechia, France, Hungary, Italy, Netherlands, Poland, United Kingdom
Pharvaris Netherlands B.V.

Active, not recruiting

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II (HAE CHAPTER-1)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

United States, Poland, Germany, Austria, Bulgaria, Canada, Ireland, Italy, United Kingdom
Allergopharma GmbH & Co. KG

Completed

Design of Optimally-diagnostic Skin Test Solutions for Diagnosis of Sensitisation to a Pollen and Dust Mite Mixture.

Type I Allergy

Germany
Innovaderm Research Inc.

Completed

Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers

Delayed Type Hypersensitivity

Canada
KalVista Pharmaceuticals, Ltd.

Terminated

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II (KVD824-201)

Angioedema, Hereditary, Types I and II

United States, Czechia, Germany, Hungary, Italy, North Macedonia, United Kingdom, Australia, Bulgaria, Canada, France, New Zealand, Puerto Rico
V.A. Nasonova Research Institute of Rheumatology...
AstraZeneca

Not yet recruiting

Evaluation of Type I IFN Level and Disease Activity in SLE Patients

Elevated Level of IFN Type I in SLE Patients
Cynosure, Inc.

Completed

Skintel Integration Study

Skin Type From I-VI on Non-hair Bearing Skin
Pharvaris Netherlands B.V.

Recruiting

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-2)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

United States, Bulgaria, Czechia, Hungary, Spain, France, Germany, Poland, Canada, Israel
Pharvaris Netherlands B.V.

Recruiting

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema (RAPIDe-3)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

United States
Piazza della Vittoria 14 Studio Medico - Ginecologia...

Completed

Knowledge and Perspective of Healthcare Professionals About Female Genital Mutation (FMG-HCPROF)

Female Genital Mutilation Type I Status | Female Genital Mutilation Type II Status | Female Genital Mutilation Type III Status

Italy
Arizona State University
Catholic Charities Phoenix; Phoenix International Refugee Committee; Refugee... and other collaborators

Completed

Female Genital Cutting in the Arizona Somali Refugee Community (FGC)

Female Genital Mutilation Type I Status | Female Genital Mutilation Type II Status | Female Genital Mutilation Type III Status

United States
Hadassah Medical Organization
Oramed Pharmaceutical Inc.

Completed

Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients

Brittle Type I Diabetes Mellitus

Israel
Hospices Civils de Lyon

Completed

Analysis of the Availability of the Treatments for ACE-I and ARB-induced Angioedema

ACE-I and ARB-induced Angioedema.

France
REGENXBIO Inc.

Active, not recruiting

RGX-111 Gene Therapy in Patients With MPS I

Hurler Syndrome | Hurler-Scheie Syndrome | Mucopolysaccharidosis Type I (MPS I)

United States, Brazil, Israel
London School of Hygiene and Tropical Medicine

Completed

Immune Responses to BCG Vaccination in Malawi and the UK

Immunity, Cellular | Hypersensitivity, Delayed Type

Malawi, United Kingdom
Nemours Children's Clinic
Thrasher Research Fund

Completed

Glutamine and Insulin Sensitivity in Type I Diabetes

Type I Diabetes Mellitus

United States
Sanofi

Completed

A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting (HomERT)

Pompe Disease | Mucopolysaccharidosis Type I (MPS I)

Italy
Wuhan Union Hospital, China

Unknown

Multi-center Study on Surgical or Non-surgical Treatment for Children Type 1 Humeral Condyle Fracture

Treatment for Type I Humeral Condyle Fracture
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen

HIV Infections

United States
Washington University School of Medicine
Patient-Centered Outcomes Research Institute; Mayo Clinic; The University of... and other collaborators

Completed

Posterior Fossa Decompression With or Without Duraplasty for Chiari Type I Malformation With Syringomyelia

Syringomyelia | Arnold-Chiari Malformation, Type 1 | Chiari Malformation Type I | Type I Arnold-Chiari Malformation

United States
Tonix Pharmaceuticals, Inc.
Premier Research Group plc

Active, not recruiting

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens (COVID-19 DTH)

Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

United States
CerbaXpert

Not yet recruiting

Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier (Pregiferon)

Woman Suffering From a Pathology Frequently Associated With the Presence of These Anti-autoantibodies Type-I Interferons
Rabin Medical Center

Completed

Closing the Loop Between Glucose Sensor and Insulin Pump-developing an Algorithm

Diabetes, Type I

Israel
Ruhr University of Bochum

Unknown

Two Measures of Tactile Acuity in CRPS Type I Patients

Healthy Controls | CRPS Type I of the Upper Extremity | Neuropathy of the Median Nerve

Germany
Corporacion Parc Tauli

Recruiting

Multicenter Observational Study Taulí-T1 Classification for the Management of pT1 Rectal Adenocarcinoma (TAUTEM-pT1)

Rectal Cancer Stage I

Spain
Medical University of Graz

Completed

A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial (ENM-HS-001)

Diabetes, Type I

Austria
Augusta University

Completed

Mechanism of Action of Biofeedback Therapy

Hypersensitivity | Constipation | Hyposensitivity

United States
University of Sao Paulo

Suspended

Biomarkers for Bipolar Disorder: Chaperones and Reticulum Endoplasmatic Stress Response CHAP´s Study (CHAPS)

Bipolar Disease Type I

Brazil

Clinical Trials on Type I Hypersensitivity

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations